Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association

Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association

Objective In rheumatoid arthritis (RA) around two-thirds of patients are autoantibody positive for rheumatoid factor, anti-citrullinated protein antibodies and/or anti-carbamylated protein antibodies. The remaining seronegative subgroup of patients is clinically heterogeneous and thus far, biomarker...

Full description

Bibliographic Details
Main Authors: Diane van der Woude, Leendert A Trouw, Tom WJ Huizinga, Annette HM van der Helm-van Mil, René EM Toes, Tineke J van Wesemael, Michelle D van den Beukel, Nicole V Borggreven, Anna Titia W Hoogslag
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/9/4/e003480.full

Internet

https://rmdopen.bmj.com/content/9/4/e003480.full

Similar Items